Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

被引：0
|
作者：
Shoko Noda-Narita
Akihiko Shimomura
Asuka Kawachi
Hitomi Sumiyoshi-Okuma
Kazuki Sudo
Tatsunori Shimoi
Emi Noguchi
Kan Yonemori
Chikako Shimizu
Yasuhiro Fujiwara
Kenji Tamura
机构：
[1] National Cancer Center Hospital,Department of Breast and Medical Oncology
[2] National Center for Global Health and Medicine,Department of Breast Medical Oncology
来源：
Breast Cancer | 2019年 / 26卷
关键词：
Trastuzumab emtansine; Metastatic breast cancer; Human epidermal growth factor 2; Trastuzumab; Pertuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：492 / 498
页数：6
相关论文
共 50 条
  • [1] Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
    Noda-Narita, Shoko
    Shimomura, Akihiko
    Kawachi, Asuka
    Sumiyoshi-Okuma, Hitomi
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Yonemori, Kan
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    BREAST CANCER, 2019, 26 (04) : 492 - 498
  • [2] Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer
    Portera, Chia C.
    Walshe, Janice M.
    Rosing, Douglas R.
    Denduluri, Neelima
    Berman, Arlene W.
    Vatas, Ujala
    Velarde, Margarita
    Chow, Catherine K.
    Steinberg, Seth M.
    Nguyen, Diana
    Yang, Sherry X.
    Swain, Sandra M.
    CLINICAL CANCER RESEARCH, 2008, 14 (09) : 2710 - 2716
  • [3] Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review
    Mathew, Jacob
    Perez, Edith A.
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 594 - 600
  • [4] Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Van den Mooter, Tom
    Teuwen, Laure-Anne
    Rutten, Annemie
    Dirix, Luc
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (05) : 749 - 760
  • [5] Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Yeo, Winnie
    Luk, M. Y.
    Soong, Inda S.
    Yuen, Tony Y. S.
    Ng, T. Y.
    Mo, Frankie K. F.
    Chan, K.
    Wong, S. Y.
    Tsang, Janice
    Leung, Carmen
    Suen, Joyce J. S.
    Ngan, Roger K. C.
    HONG KONG MEDICAL JOURNAL, 2018, 24 (01) : 56 - 62
  • [6] Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer
    Miller, Kathy D.
    Dieras, Veronique
    Harbeck, Nadia
    Andre, Fabrice
    Mahtani, Reshma L.
    Gianni, Luca
    Albain, Kathy S.
    Crivellari, Diana
    Fang, Liang
    Michelson, Glenn
    de Haas, Sanne L.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) : 1437 - +
  • [7] Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)
    Luis Baez-Vallecillo
    Akshara S. Raghavendra
    Kenneth R. Hess
    Carlos H. Barcenas
    Stacy L. Moulder
    Debu Tripathy
    Vicente Valero
    Rashmi K. Murthy
    Breast Cancer Research and Treatment, 2019, 176 : 227 - 234
  • [8] Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Wang, Min
    Wang, Kailing
    Zhu, Hong
    BREAST, 2022, 66 : 191 - 198
  • [9] Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)
    Baez-Vallecillo, Luis
    Raghavendra, Akshara S.
    Hess, Kenneth R.
    Barcenas, Carlos H.
    Moulder, Stacy L.
    Tripathy, Debu
    Valero, Vicente
    Murthy, Rashmi K.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (01) : 227 - 234
  • [10] A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
    Krop, Ian E.
    LoRusso, Patricia
    Miller, Kathy D.
    Modi, Shanu
    Yardley, Denise
    Rodriguez, Gladys
    Guardino, Ellie
    Lu, Michael
    Zheng, Maoxia
    Girish, Sandhya
    Amler, Lukas
    Winer, Eric P.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3234 - 3241
12345